Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab +/- MEDI4736 in Japanese patients with advanced solid tumors or mesothelioma
NCT02141347Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2014
- Primary completion
- Jan 2017
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of tremelimumab in solid tumor (advanced stage) and malignant mesothelioma (3 arms), sponsored by AstraZeneca. Primary endpoint: Adverse event. Started May 2014; status: completed.
02
Drugs
tremelimumab
03
Conditions
solid tumor (advanced stage)malignant mesothelioma
Beyond the preview
Go deeper on NCT02141347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02141347.